In this research, we revealed that AS-IV elevated the expression of PHD2 to alleviate PAH progression through inhibiting HIF1α and NLRP3 inflammasome, which was not clarified in the previous publications. The gene discussed is EGLN1; the disease is pulmonary arterial hypertension.